atezolizumab + radium-223 dichloride

Atezolizumab + radium-223 dichloride is an investigational **combination therapy** consisting of atezolizumab, a recombinant humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and radium-223 dichloride, an alpha-emitting radiopharmaceutical. Atezolizumab acts as an **immune checkpoint inhibitor** by binding to PD-L1 and blocking its interaction with PD-1 and B7.1 receptors, restoring anti-tumor T-cell activity. Radium-223 dichloride selectively targets areas of increased bone turnover, delivering high-energy alpha particles that cause double-stranded DNA breaks and cytotoxicity in bone metastases. The combination has been evaluated in clinical studies for metastatic castration-resistant prostate cancer (mCRPC) with bone metastases and for metastatic urothelial cancer with bone involvement, hypothesizing synergistic anti-tumor activity via combined immune modulation and targeted radiotherapeutic cytotoxicity. Early clinical studies have found the combination has increased toxicity compared to single agents and have not definitively identified additional clinical benefit in these populations[3][1][2][4].

Brand names

TecentriqXofigo

Other names

radium-223 and atezolizumabradium223 and atezolizumabradium 223 and atezolizumabXofigo and Tecentriq